[CLSTR]
< Back to situations

Monitor this situation.

[SITUATION] · [QUIET] · [HEALTH]

8 clusters · 112 sources · 46 days · First seen · Last updated

Semaglutide regulatory approvals and pricing in Brazil

Overview

Brazil’s National Health Surveillance Agency (Anvisa) has expanded the domestic market for semaglutide, a medication used to treat type 2 diabetes and weight loss. Initially, Anvisa registered five new semaglutide injectable pens—Owozy, Seemasun, Zempneo, Semavy, and Orsema—for adults with inadequately controlled type 2 diabetes. These products were approved via comparison with the reference biologic Ozempic and are assigned to various companies including Ávita Care and Sun Farmacêutica. Because these were not classified as generics, automatic pharmacy substitution does not apply. Following these registrations, Anvisa approved the country’s first generic and similar versions of the medication. EMS received registration for a generic version named Ozivy, which utilizes a synthetic version of the active ingredient and includes four different injectable pen presentations of 1.34 mg/mL in various pen and kit configurations. Additionally, Germed received approval for a similar version of the drug to be sold under the name Semaclique. Following the expiration of the substance's patent in March 2026, the market has seen further regulatory milestones. Anvisa recently approved the registration of a second generic version of semaglutide, granted to Germed Farmacêutica. This follows the EMS generic approval by just one week. The new Germed generic will be available in four injectable presentations and is expected to be priced at least 35% lower than reference products like Ozempic and Wegovy. In response to increased competition, Eurofarma has announced price reductions of up to 39% for its Poviztra product for patients enrolled in its EuroCuida support program. Further expanding the market, Anvisa approved Yluméc, a new semaglutide-based medication from EMS. Classified as a ‘clone’ similar to the EMS product Ozivy, Yluméc is indicated for adults with type 2 diabetes and will be available in weekly subcutaneous injection pens with 1.5 mL and 3 mL cartridge options.

Entities

Anvisa · Brazil · Novo Nordisk · EMS · Mantecorp

Claims

What the coverage asserts, and how many sources carry each claim.

Coverage disagrees

Sources make claims that cannot both be true. CLSTR reports the disagreement; it does not decide who is right.

  • "Anvisa approved the first generic semaglutide medication in Brazil."

    vs

    "Semaclique is the second generic semaglutide pen approved in Brazil." diariodopara.com.br · portalterradaluz.com.br · fatoamazonico.com.br · www.abcmais.com

    The first claim asserts Anvisa approved the first generic semaglutide, while the second claim asserts Semaclique is the second generic semaglutide approved.

Timeline

  1. [HEALTH] 4 sources
    Brazil expands access to obesity and diabetes treatments

    Brazil sees advancements in metabolic health treatments as Mantecorp introduces Semavy and Anvisa approves generic liraglutide medications from EMS to treat obesity and type 2 diabetes.

  2. [HEALTH] 3 sources
    Mantecorp launches Semavy weight-loss pen in Brazil

    Mantecorp has launched Semavy, a semaglutide weight-loss pen in Brazil. Experts highlight the need for skin care during rapid weight loss and note potential sensory changes in users.

  3. [HEALTH] 7 sources
    Mantecorp launches Semavy semaglutide medication in Brazil

    Mantecorp has launched Semavy, a semaglutide medication for diabetes and weight loss, in Brazil at a lower cost than previous reference drugs following the expiration of the molecule's patent.

  4. [HEALTH] 29 sources
    EMS semaglutide medication Yluméc approved by Anvisa

    Anvisa approved EMS's new semaglutide medication, Yluméc, for treating type 2 diabetes. The drug will be produced in Hortolândia, Brazil, in various pen formats, with pricing still pending CMED definition.

  5. [HEALTH] 21 sources
    Anvisa approves second generic semaglutide in Brazil

    Anvisa has approved Germed Farmacêutica's semaglutide generic in Brazil, increasing competition for diabetes and obesity treatments following the expiration of original patents.

  6. [BUSINESS] 3 sources
    Eurofarma reduces prices for semaglutide medication Poviztra

    Eurofarma has reduced prices for its semaglutide-based obesity medication, Poviztra, by up to 39% in Brazil as competition increases following patent expirations.

  7. [HEALTH] 64 sources
    Anvisa approves Brazil's first generic semaglutide medication

    Anvisa has approved Brazil's first generic semaglutide medication from EMS and a similar version from Germed, named Semaclique, for treating type 2 diabetes.

  8. [HEALTH] 11 sources
    Brazil's Anvisa approves five new semaglutide injection pens

    Brazil's Anvisa registered five semaglutide injection pens (Owozy, Seemasun, Zempneo, Semavy, Orsema) for type‑2 diabetes, marking the largest GLP‑1 agonist approval batch and expanding market competition.

Sources

acessa.com · acordacidade.com.br · amazonianarede.com.br · api.metro1.com.br · apostagem.com.br · aqgymnastics.com · atarde.com.br · atibaia.com.br · bahianoticias.com.br · bemparana.com.br · biathlon-news.de · blogdomarioadolfo.com.br · bpmoney.com.br · brasil247.com · casavogue.globo.com · cbn.globo.com · chicoterra.com · cmjornal.pt · collegeaccounting.com · correiodecarajas.com.br · crs.cz · delas.ig.com.br · destakjornal.com.br · dev.tnonline.com.br · diariodecanoas.com.br · diariodopara.com.br · diarioonline.com.br · drd.com.br · easycabs.com.cy · ederluiz.com.vc · elimeira.com.br · enfoquems.com.br · epocanegocios.globo.com · esportenaredemt.com.br · exame.com · fatoamazonico.com.br · fei.es · folhabv.com.br · folhadoleste.com.br · fraserlax.com · gazetaderiopreto.com.br · gazetaweb.com · geochimie.fr · grupoparanacomunicacao.com.br · hopkinsmedicine.org · incorporeestetica.com.br · infomoney.com.br · infonet.com.br

This summary has been updated 8 times: see revision history